Brief: Gamida Cell Reports Preliminary Data From Phase 1 Study Of Natural Killer Cell Therapy Candidate Gda-201
16/10/2023 22:54
Oct 16 (Reuters) - Gamida Cell Ltd GMDA.O :
* GAMIDA CELL REPORTS PRELIMINARY DATA FROM PHASE 1 STUDY OF
NATURAL KILLER (NK) CELL THERAPY CANDIDATE GDA-201
* GAMIDA CELL LTD - FULL DATA READOUT OF PHASE 1 STUDY
EXPECTED IN
Q1 2024
* GAMIDA CELL LTD- DATA SHOW PROMISING EARLY EVIDENCE OF
ANTI-TUMOR ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY B CELL
NON-HODGKIN LYMPHOMA
* GAMIDA CELL LTD: ANTICIPATE SHARING FULL PHASE I DATA IN
EARLY
2024
Source text for Eikon: ID:nBw3tC0X0a
Further company coverage: GMDA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Gamida Cell
See all newsBrief: Gamida Cell Appoints Joe Wiley As CEO
Brief: Gamida Cell Says District Court Of Beersheba, Israel Entered Judgment In Restructuring Proceeding
Israeli ADRs up on hopes of de-escalation in Israel-Iran tensions
Brief: Aquestive Therapeutics Strengthens Board Of Directors With Experienced Biotech Executive
Brief: Gamida Cell Ltd Says Received Notice From Nasdaq Notifying Co That It Determined Co’S Ordinary Shares Will Be Delisted From Nasdaq